Carl Borrebaeck is a successful serial entrepreneur, having previously founded BioInvent International AB, Alligator BioScience AB, and Immunovia AB. BioInvent was awarded the prestigious 2009 Scrips “Licensing Deal of the Year” and Immunovia the "2016 Stars of Innovation Prize". Prof. Borrebaeck is a 2009 recipient of the AkzoNobel Science Award and was awarded the 2012 Gold Medal from the RoyalAcademy of Engineering Sciences in recognition of his ground-breaking research regarding biomarkers. In addition, Prof. Borrebaeck is the previous Vice-President of Lund University, Sweden; Director of CREATE Health, a Translational Cancer Center.
Ian Kimber is currently Professor of Toxicology and Associate Dean for Business Development in the Faculty of Life Sciences at the University of Manchester.
He has broad research interests at the interface between toxicology and immunology, with a particular focus on allergy and inflammation. Professor Kimber holds, and has held, a variety of positions on national and international expert and scientific advisory committees. Professor Kimber was previously President of the British Toxicology Society (2012-2014), and Chairman of the Board of the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (2008-2013). He has published over 625 research papers, review articles and book chapters, and serves currently on the editorial boards of toxicology, immunology, dermatology and pathology journals and he has received a number of awards and prizes.
Carl-Henric Nilsson, PhD Industrial management, Associate Professor Lund University, School of Economics and Management. CEO Kunskapspartner AB. Chairman Kunskapspartner Holding AB, Boardmember FX International AB, Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with Entrepreneurs on a global basis with a broad contact net, especially in China and the United States.
Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.
Malin Lindstedt is one of the founders of SenzaGen AB and inventor of GARD. She has for the last 12 years been involved in the development of biomarker-based assays for prediction of sensitization as alternatives to animal experimentation. She is a cellular immunologist and in vitro testing specialist. In addition to her role as advisor and deputy board member in SenzaGen AB, she functions as Study Director and research group leader at Department of Immunotechnology within the Faculty of Engineering at Lund University, Sweden. Her research is particularly focused on the role of dendritic cell subpopulations in sensitization and cancer, and strategies to utilize and target these cells in vitro for development of predictive assays and immunotherapy. Malin Lindstedt holds a M.Sc. in Engineering Biology from Umeå University and a PhD in Immunotechnology, LTH.